USPTO serial 99862478
MRNACT
Reviewed by CopyMark Law Group
Status 641Office Action
- Filing date
- Status date
- Registration date
- —
- Examiner
- OPUTA, CHIOMA N
- Law office
- TMEG LAW OFFICE 103
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Need help with MRNACT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Holly Springs, NC, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Nancy Sabarra
Nancy Sabarra Fross Zelnick Lehrman & Zissu, P.C.151 West 42nd St., 17th Fl.New York, NY 10036United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemical ingredients; active chemical and biological ingredients for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) encapsulated in lipid nanoparticles for preventing and treating viruses and respiratory disorders; biochemical preparations for in vivo, ex vivo, on vivo, and in vitro scientific research and medical research; biochemicals for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders; lipid nanoparticles for scientific, laboratory or medical research use; active biological ingredients for use in the manufacture of pharmaceuticals, namely, self-amplifying messenger RNA (sa-mRNA) encapsulated in a lipid nanoparticle composed of a cationic lipid and three helper lipids for use in the manufacture of pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viruses and respiratory disorders; biochemicals for in vivo, ex vivo, on vivo or in vitro scientific research; biochemicals for medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses and respiratory disorders | ACTIVE | — |
| 005 | Adjuvants; vaccine adjuvants; vaccines; drug carriers for medical use, namely, drug delivery agents consisting of lipid nanoparticles that facilitate delivery of a wide range of pharmaceuticals; medical, biological, and pharmaceutical preparations for medical use, namely, medical, biological and pharmaceutical preparations containing messenger RNA (mRNA) for preventing and treating viral diseases and respiratory disorders; mRNA-based therapeutics in the nature of therapeutic agents and therapeutic agents for use in vivo, ex vivo, or in situ for the prevention and treatment of viruses and respiratory disorders; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations for intracellular delivery of self-amplifying messenger RNA (sa-mRNA) for preventing and treating viral diseases all for pharmaceutical, medical or medical diagnostic purposes; lipid nanoparticles for use as drug delivery carriers sold as an integral component of pharmaceutical preparations; pharmaceutical preparations, namely, messenger RNA (mRNA) therapeutic agents and delivery agents comprised of lipid nanoparticle carriers and polymers for the delivery of mRNA to human cells | ACTIVE | — |
| 042 | Research and development; pharmaceutical research and development; medical research services; biotechnology research; scientific research for medical purposes; design and development of medical technology; design, engineering, research, and development services in the field of nucleic acid sciences for medical and scientific applications; providing medical and scientific research in the fields of pharmaceuticals and vaccines | ACTIVE | — |
| 044 | Medical services; medical information; providing a website featuring medical information | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 14, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 14, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 7, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 6, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 3, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jun 3, 2026 | NWAP | NEW APPLICATION ENTERED | — |